Ownership history in MACQUARIE GROUP LTD Β· 24 quarters on record
This page tracks every 13F SEC filing in which MACQUARIE GROUP LTD reported a position in AMICUS THERAPEUTICS INC (FOLD). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β sourced directly from SEC EDGAR 13F filings.
π MACQUARIE GROUP LTD underperformed the S&P 500 by β5.6% annually on this FOLD position. Timing score: 65% (15/23 decisions correct). Average cost basis: $13.70. Maximum drawdown during holding period: β75.2%.
β Significantly underperformed the S&P 500 by 5.6% ann.
23 quarters analyzed
β
Decent timing β more right than wrong on entries and exits.
15 of 23 add/trim decisions correct
Best entry: $5.73 (2025 Q2) Β· Worst: $23.09 (2020 Q4)
πͺ Held through 1 major drawdown (>20%). Strong conviction under pressure.
17 adds Β· 7 trims. Bought during 12 of 14 down-price quarters. π Consistently bullish β fund kept accumulating this position.
βοΈ Portfolio weight has remained relatively stable β conviction maintained.
Currently 0.04% of portfolio
β Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ 4 (annualised). Not investment advice.
As of 2025 Q4 β sorted by position size